[GUEST ACCESS MODE: Data is scrambled or limited to provide examples. Make requests using your API key to unlock full data. Check https://lunarcrush.ai/auth for authentication information.]  d_stock [@d_stock07734](/creator/twitter/d_stock07734) on x XXX followers Created: 2025-07-23 17:14:30 UTC Absolutely brilliant post. Here is the job posting from Merck three years ago. It seems like the manufacturing facilities that Merck was trying to construct at Merck West Point Campus are just pilot models that Merck intend to reproduce in other locations too. Simply going through all the following three Direct-like trials and taking a look at the combination adopted, how could anyone still have doubt? Read again the grant description submitted by Mill Creek Life Sciences. In the last a couple of years, they have been building alleogeneic tumor lysate library for other types of solid tumors! Dendritic Cell Therapy With Pembrolizumab for Metastatic or Unresectable Melanoma Sponsor Mayo Clinic Study Start (Actual): 2017-11-15 Primary Completion (Actual): 2020-06-14 Principal Investigator:Matthew S. Block, M.D., Ph.D.,Mayo Clinic Vaccine Therapy With or Without Cryosurgery in Treating Patients With Residual, Relapsed, or Refractory B-Cell Non-Hodgkin Lymphoma Study Start (Actual): 2010-11 Primary Completion (Actual): 2015-11-24 Study Chair:Yi Lin, M.D.,Mayo Clinic Dendritic cell vaccine treatment for indolent B cell non-hodgkin lymphoma: clinical trial in progress Dendritic Cell Therapy, Cryosurgery, and Pembrolizumab in Treating Patients With Non-Hodgkin Lymphoma Phase I/II Study of Dendritic Cell Therapy Delivered Intratumorally After Cryoablation and Anti-PD-1 Antibody (Pembrolizumab) for Patients With Non-Hodgkin Lymphoma Study Start (Actual): 2017-08-15 Primary Completion (Actual): 2022-01-25 Principal Investigator:Yi Lin, MD, PhD,Mayo Clinic Glioblastoma (GBM) is a type of brain cancer with no known cure. Recently, an innovative vaccine combining a patient’s own dendritic cells (DCs) with proteins from allogeneic tumor cells, developed at the Mayo Clinic, showed great promise in early clinical trials. This therapy involves collecting a patient’s dendritic cells, preparing tumor proteins as antigens, and delivering the activated dendritic cells back to the patient. The research team has successfully created platform technology for this GBM therapy using an advanced cell culture technique. Building on this success, the team now aims to develop antigen libraries for other tumor types, expanding their portfolio of cancer vaccines to treat a broader range of cancers and make these therapies more readily available to patients.  XXXXX engagements  **Related Topics** [$nwbo](/topic/$nwbo) [hub](/topic/hub) [$7846t](/topic/$7846t) [$mrk](/topic/$mrk) [stocks healthcare](/topic/stocks-healthcare) [Post Link](https://x.com/d_stock07734/status/1948069221511868610)
[GUEST ACCESS MODE: Data is scrambled or limited to provide examples. Make requests using your API key to unlock full data. Check https://lunarcrush.ai/auth for authentication information.]
d_stock @d_stock07734 on x XXX followers
Created: 2025-07-23 17:14:30 UTC
Absolutely brilliant post.
Here is the job posting from Merck three years ago. It seems like the manufacturing facilities that Merck was trying to construct at Merck West Point Campus are just pilot models that Merck intend to reproduce in other locations too. Simply going through all the following three Direct-like trials and taking a look at the combination adopted, how could anyone still have doubt? Read again the grant description submitted by Mill Creek Life Sciences. In the last a couple of years, they have been building alleogeneic tumor lysate library for other types of solid tumors!
Dendritic Cell Therapy With Pembrolizumab for Metastatic or Unresectable Melanoma
Sponsor Mayo Clinic Study Start (Actual): 2017-11-15 Primary Completion (Actual): 2020-06-14 Principal Investigator:Matthew S. Block, M.D., Ph.D.,Mayo Clinic
Vaccine Therapy With or Without Cryosurgery in Treating Patients With Residual, Relapsed, or Refractory B-Cell Non-Hodgkin Lymphoma
Study Start (Actual): 2010-11 Primary Completion (Actual): 2015-11-24 Study Chair:Yi Lin, M.D.,Mayo Clinic
Dendritic cell vaccine treatment for indolent B cell non-hodgkin lymphoma: clinical trial in progress
Dendritic Cell Therapy, Cryosurgery, and Pembrolizumab in Treating Patients With Non-Hodgkin Lymphoma Phase I/II Study of Dendritic Cell Therapy Delivered Intratumorally After Cryoablation and Anti-PD-1 Antibody (Pembrolizumab) for Patients With Non-Hodgkin Lymphoma
Study Start (Actual): 2017-08-15 Primary Completion (Actual): 2022-01-25 Principal Investigator:Yi Lin, MD, PhD,Mayo Clinic
Glioblastoma (GBM) is a type of brain cancer with no known cure. Recently, an innovative vaccine combining a patient’s own dendritic cells (DCs) with proteins from allogeneic tumor cells, developed at the Mayo Clinic, showed great promise in early clinical trials. This therapy involves collecting a patient’s dendritic cells, preparing tumor proteins as antigens, and delivering the activated dendritic cells back to the patient. The research team has successfully created platform technology for this GBM therapy using an advanced cell culture technique. Building on this success, the team now aims to develop antigen libraries for other tumor types, expanding their portfolio of cancer vaccines to treat a broader range of cancers and make these therapies more readily available to patients.
XXXXX engagements
Related Topics $nwbo hub $7846t $mrk stocks healthcare